High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00354744
First received: July 19, 2006
Last updated: November 20, 2013
Last verified: November 2013
  Purpose

RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide, etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose combination chemotherapy together with radiation therapy may kill more tumor cells.

PURPOSE: This phase III trial is studying how well giving high-dose combination chemotherapy together with radiation therapy works in treating patients with newly diagnosed metastatic rhabdomyosarcoma or ectomesenchymoma.


Condition Intervention Phase
Sarcoma
Biological: dactinomycin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: irinotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy
Biological: filgrastim
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Tumor Response Rate [ Time Frame: Protocol week 6 evaluation ] [ Designated as safety issue: No ]
    Volumetric measurements of the primary tumor using an elliptical model (0.5 x the product of the 3 largest perpendicular diameters) to assess response to neoadjuvant therapy. The RECIST (Response Evaluation Criteria in Solid Tumors) from the NCI will be used for assessment of the size of measurable metastases, including nodal metastases. Primary Tumor Measurement: Technical guidelines for cross-sectional imaging computed tomography (CT) slice thickness should be 5mm or less and the diameter of the "measurable" mass should be at least twice the reconstructed slice thickness. Smaller masses are considered detectable, but will be counted as "non-measurable." Complete Response (CR): Complete disappearance of the tumor confirmed at >4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Progressive Disease (PD): At least 40% increase in tumor volume compared to the smallest volume obtained since the beginning.

  • Estimate of the Percent of Patients Event Free at 4 Years Following Study Entry [ Time Frame: 4 years ] [ Designated as safety issue: No ]
    Event-free survival: Time to recurrence or death as a first event.


Secondary Outcome Measures:
  • Early Disease Control [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Improve the early disease control interval for patients with newly diagnosed, high-risk, metastatic rhabdomyosarcoma or ectomesenchymoma using intensive, interval-compression therapy (comprising vincristine, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin) that permits maximal early exposure to known effective agents.

  • Feasibility [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Determine the feasibility of concurrent irinotecan hydrochloride and radiotherapy in these patients.

  • Toxicity [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Assess immediate- and short-term toxicities of concurrent irinotecan hydrochloride and radiotherapy in these patients


Enrollment: 109
Study Start Date: July 2006
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: High Risk Rhabdomyosarcoma
Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
Biological: dactinomycin

Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.

Day 1 of Weeks 35, 38, 41 and 44.

Given IV

Other Names:
  • Actinomycin-D
  • Cosmegen
  • NSC #3053
Drug: cyclophosphamide

Age based dosage: ≥ 3 years 1200 mg/m2, <3 years 40 mg/kg.

Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.

Given IV

Other Names:
  • Cytoxan
  • NSC #26271
Drug: doxorubicin hydrochloride

Age based dosage: ≥ 1 year: 37.5mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².

Days 1 and 2 of weeks 7, 11, 15, 28 and 32.

Given IV

Other Names:
  • Adriamycin
  • NSC #123127
Drug: etoposide

Age based dosage: ≥ 1 year: 100 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.

Days 1-5 of weeks 9, 13, 17, 26 and 30.

Given IV

Other Names:
  • VePesid
  • Etopophos
  • VP-16
  • NSC #141540
Drug: ifosfamide

Age based dosage: ≥ 1 year: 1800 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.

Days 1-5 of weeks 9, 13, 17, 26 and 30.

Given IV

Other Names:
  • Isophosphamide
  • Iphosphamide
  • Z4942
  • Ifex
  • NSC #109724
Drug: irinotecan hydrochloride

Dosage 50 mg/m2-max dose 100 mg/day.

Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.

Given IV

Other Names:
  • CPT-11
  • Camptothecin-11
  • 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin
  • Camptosar
  • NSC #616348
Drug: vincristine sulfate

Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and < 3 years 0.05 mg/kg (max dose 2 mg), < 1 year 0.025 mg/kg.

Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.

Given IV

Other Names:
  • Oncovin
  • VCR
  • LCR
  • NSC #67574
Procedure: conventional surgery
Resection of the primary tumor with a surrounding "envelope" of normal tissue
Radiation: radiation therapy
Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
Biological: filgrastim

5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.

Given subcutaneously.

Other Names:
  • Granulocyte Colony-Stimulating Factor
  • r-metHuG-CSF
  • G-CSF
  • Neupogen
  • NSC #614629

Detailed Description:

OBJECTIVES:

Primary

  • Improve the early disease control interval for patients with newly diagnosed, high-risk, metastatic rhabdomyosarcoma or ectomesenchymoma using intensive, interval-compression therapy (comprising vincristine, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin) that permits maximal early exposure to known effective agents.
  • Determine the feasibility of concurrent irinotecan hydrochloride and radiotherapy in these patients.
  • Assess immediate- and short-term side effects of concurrent irinotecan hydrochloride and radiotherapy in these patients.

Secondary

  • Expand the available data for response to irinotecan hydrochloride and vincristine in previously untreated patients with high-risk rhabdomyosarcoma.
  • Evaluate, prospectively, and validate gene expression values with the intent to define the best diagnostic predictors and more powerful prognostic classifiers.

OUTLINE: This is a prospective, nonrandomized, multicenter study. Patients are stratified according to prognostic factors predictive of outcome (e.g. histology, bone/bone marrow involvement, and number of metastatic sites).

Patients receive high-dose chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; and ifosfamide IV over 1 hour and etoposide IV over 30-60 minutes on days 1-5 of weeks 9, 13, 17, 26, and 30. Patients also receive doxorubicin hydrochloride IV continuously over 24 hours on days 1 and 2 of weeks 7*, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; and dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44 in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously in weeks 7-9, 11-13, 15-17, 22, 26, 28-30, 32, 33, 35, 38, and 41-44 beginning 24-36 hours after the last chemotherapy dose and continuing until blood counts recover.

NOTE: *Patients undergoing early radiotherapy for intracranial extension do not receive doxorubicin in week 7.

Beginning at week 20 (or week 1 for patients with parameningeal tumors with intracranial extension [or spinal cord compression] requiring emergency radiotherapy), patients also undergo radiotherapy once a day, 5 days a week, for approximately 5½ weeks. Some patients may also undergo second-look surgery.

After completion of study treatment, patients are followed periodically for ≥ 10 years.

PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   up to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed high-risk rhabdomyosarcoma or ectomesenchymoma

    • Prior enrollment on COG-D9902 to confirm local histological diagnosis required

      • Tissue must be submitted for pathologic review within 2 days of patient registration on COG-D9902
    • Newly diagnosed disease
    • Metastatic disease (stage IV, clinical group IV)
  • Has undergone initial surgical procedure (including biopsy) that provided the definitive diagnosis within the past 42 days
  • Parameningeal and paraspinal tumors allowed

    • Patients with parameningeal (without intracranial extension [ICE]) and paraspinal tumors should begin study chemotherapy at week 1 and radiotherapy at week 20
  • Patients with evidence of ICE, as defined by contrast MRI showing that primary tumor touches, displaces, invades, distorts, or otherwise causes a signal abnormality of the dura in contiguity to the primary site in brain or spinal cord, are eligible

    • ICE is presumed to exist if the cerebrospinal fluid cytopathology is positive for tumor at diagnosis
  • Patients requiring emergency radiotherapy are eligible

    • Patients requiring emergency radiotherapy (for intracranial extension or spinal cord impingement) should begin study chemotherapy at week 1 (irinotecan hydrochloride and vincristine) concurrently with radiation therapy

PATIENT CHARACTERISTICS:

  • ECOG or Zubrod performance status (PS) 0-2 (Lansky PS 50-100% for patients < 10 years of age and Karnofsky PS 50-100% for patients ≥ 10 years of age)
  • Absolute neutrophil count ≥ 750/mm³*
  • Platelet count ≥ 75,000/mm³*
  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min (≥ 40 mL/min for infants < 1 year of age)
  • Patients with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract
  • SGPT < 2.5 times normal
  • Bilirubin < 1.5 mg/dL
  • Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by MUGA
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during study and for ≥ 1 month after study completion
  • No evidence of uncontrolled infection
  • Able to undergo radiotherapy NOTE: *Abnormal blood counts allowed if there is bone marrow biopsy or aspirate proven bone marrow involvement by rhabdomyosarcoma

PRIOR CONCURRENT THERAPY:

  • No prior chemotherapy except steroids
  • No prior radiotherapy
  • No concurrent aprepitant during ifosfamide or doxorubicin hydrochloride chemotherapy
  • No concurrent dexrazoxane
  • No concurrent sargramostim (GM-CSF) or pegfilgrastim
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00354744

  Show 166 Study Locations
Sponsors and Collaborators
Children's Oncology Group
Investigators
Study Chair: Brenda Weigel, MD Masonic Cancer Center, University of Minnesota
Study Chair: Carola A Arndt, MD Mayo Clinic
  More Information

Additional Information:
Publications:
Weigel B, Lyden E, Anderson JR, et al.: Early results from Children's Oncology Group (COG) ARST0431: intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). [Abstract] J Clin Oncol 28 (Suppl 15): A-9503, 2010.

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT00354744     History of Changes
Other Study ID Numbers: ARST0431, CDR0000489215, COG-ARST0431
Study First Received: July 19, 2006
Results First Received: September 3, 2013
Last Updated: November 20, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Oncology Group:
adult rhabdomyosarcoma
previously untreated childhood rhabdomyosarcoma
adult malignant mesenchymoma
childhood malignant mesenchymoma
metastatic childhood soft tissue sarcoma
stage IV adult soft tissue sarcoma

Additional relevant MeSH terms:
Rhabdomyosarcoma
Sarcoma
Myosarcoma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Dactinomycin
Doxorubicin
Etoposide phosphate
Isophosphamide mustard
Irinotecan
Camptothecin
Cyclophosphamide
Etoposide
Ifosfamide
Vincristine
Lenograstim
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on July 24, 2014